Press release archive 2006

Tuesday, 19 December 2006
EPO Announces European Nexium® Substance Patent Decision AstraZeneca today announced that the European Patent Office (EPO) has ruled that one of the European substance patents for Nexium® (EP 0652872) will be rejected, following an appeal from the German generic manufacturer Ratiopharm. The original patent expiry for this patent was 2014.
Monday, 11 December 2006
Egyptian Health Minister Opens AstraZeneca’s New $32M Manufacturing Plant near Cairo Egyptian Health Minister Dr. Hatem Mostafa El-Gabaly today opened a new $32 million tablet factory built by AstraZeneca near Cairo – the company’s first manufacturing investment in the Middle East. David Brennan, Chief Executive Officer of AstraZeneca, also attended the opening ceremony at the factory in 6th of October City.
Tuesday, 5 December 2006
AstraZeneca Commitment To China Recognised by Cathay Pacific Award In recent years AstraZeneca has become the leading multinational pharmaceutical company in China in prescription sales, has established 25 sales offices in major cities across the country, created a $134m state-of-the-art manufacturing facility in Wuxi, Jiang Su Province, and has committed a further $100m to Research and Development.
Monday, 4 December 2006
AstraZeneca Licenses Rights for the Development and Commercialisation of CUBICIN® in China AstraZeneca today announced that it has entered into a license agreement with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) for the development and commercialisation of the antibiotic CUBICIN® (daptomycin for injection) in China and certain other countries in Asia, the Middle East and Africa not covered by existing CUBICIN international partnering agreements. The agreement does not include Japan, which is yet to be partnered. CUBICIN is the first antibiotic in a new class of antiinfectives called lipopeptides.
Wednesday, 22 November 2006
AstraZeneca signs distribution agreement with Par Pharmaceutical for an authorized generic version of TOPROL-XL AstraZeneca today announced it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of metoprolol succinate in the United States. Currently, the authorized generic product will be distributed in the 25 mg dosage strength. The signing of this agreement does not affect the availability of AstraZeneca’s branded version of metoprolol succinate, TOPROL-XL. AstraZeneca will continue to manufacture and make TOPROL-XL available in the United
Friday, 3 November 2006
AstraZeneca Updates CytoFab™ Development Programme AstraZeneca today announced its intention to expand the development plan for CytoFab™, a treatment for severe sepsis, with the addition of a 480 - patient Phase II study programme.
Thursday, 26 October 2006
AstraZeneca Announces SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke Results from the SAINT II ( S troke A cute I schemic N XY-059 T reatment) trial, announced today by AstraZeneca, showed that the investigational drug NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability, as assessed by the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94) compared to placebo.
Thursday, 26 October 2006
Third Quarter and Nine Months Results 2006 Download the narrative and the figures
Friday, 20 October 2006
FDA Approves AstraZeneca’s SEROQUEL® for Bipolar Depression Treatment AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.
Thursday, 19 October 2006
AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL SR™ for the Treatment of Schizophrenia AstraZeneca today announced further submissions to Regulatory Authorities for the approval of the sustained release (SR) once-daily formulation of SEROQUEL® for the treatment of patients with schizophrenia, including Canada and a Marketing Authorisation Application (MAA) in the European Union (EU) under Mutual Recognition Procedure (MRP). The submission will cover all markets in the EU where SEROQUEL® is currently approved.